| Literature DB >> 31562236 |
Christopher Andrew Lamb1,2, Nicholas A Kennedy3,4, Tim Raine5, Philip Anthony Hendy6,7, Philip J Smith8, Jimmy K Limdi9,10, Bu'Hussain Hayee11,12, Miranda C E Lomer12,13, Gareth C Parkes14,15, Christian Selinger16,17, Kevin J Barrett18, R Justin Davies5,19, Cathy Bennett20,21, Stuart Gittens22, Malcolm G Dunlop23,24, Omar Faiz7,25, Aileen Fraser26, Vikki Garrick27, Paul D Johnston28, Miles Parkes5, Jeremy Sanderson12,13, Helen Terry28, Daniel R Gaya29,30, Tariq H Iqbal31,32, Stuart A Taylor33,34, Melissa Smith35,36, Matthew Brookes37,38, Richard Hansen27,30, A Barney Hawthorne39.
Abstract
Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn's and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn's disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn's disease, including patients, their families and friends. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: 5-ASA; 5-aminosalicylate; CMV; Crohn’s disease, CD; JAK; Ulcerative colitis, UC; adalimumab; adherence; adolescent; adult; anaemia; anti-TNF; anti-drug antibodies; antibiotic; antibiotics; azathioprine; biomarker; breastfeeding; budesonide; calprotectin; cancer; care; chemoprevention; ciclosporin; classification; clostridium difficile; cognitive behavioural therapy, CBT; colectomy; colitis; colonoscopy; computerised tomography, CT; corticosteroid; cyclosporine; cytomegalovirus; diagnosis; diet; endoscopic; endoscopy; enema; faecal microbial transplant; fatigue; fetus; fistula; granuloma; guideline; hydrocortisone; ileitis; inflammatory bowel disease, IBD; infliximab; integrin; janus kinase inhibator; magnetic resonance, MR; management; mercaptopurine; mesalazine; methylprednisolone; monitoring; multidisciplinary team, MDT; nutrition; perianal; pouch; pouchitis; prednisolone; pregnancy; primary stress; probiotic; psychology; psychotherapy; self-management; shared care; sigmoidoscopy; smoking; stress; stricture; suppository; surgery; surveillance; telephone clinic; therapeutic drug monitoring; therapy; thiopurine; tofacitinib; tuberculosis, TB; ultrasound; ustekinumab; vaccination; vaccine; vedolizumab; virtual clinic; vitamin D
Mesh：
Year: 2019 PMID： 31562236 PMCID： PMC6872448 DOI： 10.1136/gutjnl-2019-318484
Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059